Targeted Apoptosis of Ductular Reactive Cells Reduces Hepatic Fibrosis in a Mouse Model of Cholestasis
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background and Aims: In cholestatic liver diseases, ductular reactive (DR) cells extend into the hepatic parenchyma and promote inflammation and fibrosis. We have previously observed that multidrug‐resistant 2 (Mdr2−/− ) double knockout (DKO) mice lacking tumor necrosis factor–related apoptosis‐inducing ligand receptor (Tr−/− ) display a more extensive ductular reaction and hepatic fibrosis compared to Mdr2−/− mice. This observation suggests that the magnitude of the DR‐cell population may be regulated by apoptosis. Approach and Results: To examine this concept, we cultured epithelial cell adhesion molecule–positive reactive cholangioids (ERCs) obtained from wild‐type (WT), Tr−/− , Mdr2−/− and DKO mice. Single‐cell transcriptomics and immunostaining of both WT and DKO ERCs confirmed their DR‐cell phenotype. Moreover, DKO ERCs displayed a unique translational cluster with expression of chemokines, indicating a reactive state. Incubation with the myeloid cell leukemia 1 (MCL1) inhibitor S63845, a proapoptotic BH3‐mimetic therapy, significantly decreased DKO and Mdr2−/− ERC viability compared to WT. Intravenous administration of S63845 significantly reduced the DR‐cell population and markers of inflammation and liver fibrosis in Mdr2−/− and DKO mice. Furthermore, DKO mice treated with S63845 displayed a significant decrease in hepatic B lymphocytes compared to untreated mice as assessed by high‐definition mass cytometry by time‐of‐flight. Coculture of bone marrow–derived macrophages with ERCs from DKO mouse livers up‐regulated expression of the B cell–directed chemokine (C‐C motif) ligand 5. Finally, DR cells were noted to be primed for apoptosis with Bcl‐2 homologous antagonist/killer activation in vitro and in vivo in primary sclerosing cholangitis liver specimens. Conclusions: DR cells appear to play a key role in recruiting immune cells to the liver to actively create an inflammatory and profibrogenic microenvironment. Pharmacologic targeting of MCL1 in a mouse model of chronic cholestasis reduces DR‐cell and B‐cell populations and hepatic fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Singh, R., Letai, A., & Sarosiek, K. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0089-8 · Cited by 2,111 · cited 1×
“(13,14) (Cells primed for apoptosis are uniquely susceptible to proapoptotic stimuli.(15)) Although exogenous TRAIL administration could represent an approach to reduce the DR-cell population, systemic treatments with exogenous TRAIL agonists are often hepatotoxic,(16) rendering this approach problematic.”
BackgroundThe MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047 · cited 8×
“The switch from survival to apoptosis is triggered when BH3-only proteins, up-regulated by cellular stress signals, neutralize prosurvival proteins such as MCL1.”
BackgroundMethodInfluentialThe BCL-2 arbiters of apoptosis and their growing role as cancer targets
Adams, J. M., & Cory, S. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.161 · Cited by 530
Antibody-independent functions of B cells: a focus on cytokines
Shen, P., & Fillatreau, S. (2015) · Nature Reviews Immunology · doi:10.1038/nri3857 · Cited by 508
Richardson, M. M., Jonsson, J. R., Powell, E. E., Brunt, E. M., Neuschwander–Tetri, B. A., Bhathal, P. S., Dixon, J. B., Weltman, M. D., Tilg, H., Moschen, A. R., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.012 · Cited by 482 · cited 1×
“1027 liver disease.(9,37-39) We report that specifically targeting DR cells by the MCL1 inhibitor S63845 results in a robust reduction in DR cells and fibrosis in Mdr2−/− and DKO mice.”
BackgroundHepatic progenitor cells of biliary origin with liver repopulation capacity
Lu, W.-Y., Bird, T. G., Boulter, L., Tsuchiya, A., Cole, A. M., Hay, T., Guest, R. V., Wojtacha, D., Man, T. Y., Mackinnon, A., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3203 · Cited by 479
Ductular reaction in liver diseases: pathological mechanisms and translational significances
Sato, K., Marzioni, M., Meng, F., Francis, H., Glaser, S., & Alpini, G. (2019) · Hepatology · doi:10.1002/hep.30150 · Cited by 423 · cited 5×
“1027 liver disease.(9,37-39) We report that specifically targeting DR cells by the MCL1 inhibitor S63845 results in a robust reduction in DR cells and fibrosis in Mdr2−/− and DKO mice.”
BackgroundInfluentialClouston, A. D., Powell, E. E., Walsh, M. J., Richardson, M. M., Demetris, A. J., & Jonsson, J. R. (2005) · Hepatology · doi:10.1002/hep.20650 · Cited by 361
Attenuated liver fibrosis in the absence of B cells
Novobrantseva, T. I. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24798 · Cited by 277
Planas-Paz, L., Sun, T., Pikiolek, M., Cochran, N. R., Bergling, S., Orsini, V., Yang, Z., Sigoillot, F., Jetzer, J., Syed, M., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.04.005 · Cited by 216
Bird, T. G., Lu, W.-Y., Boulter, L., Gordon-Keylock, S., Ridgway, R. A., Williams, M. J., Taube, J., Thomas, J. A., Wojtacha, D., Gambardella, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302168110 · Cited by 166
Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease
Takeda, K., Kojima, Y., Ikejima, K., Harada, K., Yamashina, S., Okumura, K., Aoyama, T., Frese, S., Ikeda, H., Haynes, N. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802702105 · Cited by 148
Moncsek, A., Al‐Suraih, M. S., Trussoni, C. E., O'Hara, S. P., Splinter, P. L., Zuber, C., Patsenker, E., Valli, P. V., Fingas, C. D., Weber, A., et al. (2018) · Hepatology · doi:10.1002/hep.29464 · Cited by 136
Self-citationFaggioli, F., Palagano, E., Di Tommaso, L., Donadon, M., Marrella, V., Recordati, C., Mantero, S., Villa, A., Vezzoni, P., & Cassani, B. (2018) · Hepatology · doi:10.1002/hep.29636 · Cited by 90 · cited 2×
“B lymphocytes have been implicated in promoting hepatic fibrosis in various models of liver injury, including Mdr2−/− mice.(23,24) Distinct subsets of cells with effector and regulatory functions exist within the B-cell population.”
Background
Cited by
Cell Death in Liver Diseases: A Review
Shojaie, L., Iorga, A., & Dara, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249682 · Cited by 293
Central role for cholangiocyte pathobiology in cholestatic liver diseases
Jalan-Sakrikar, N., Guicciardi, M. E., O’Hara, S. P., Azad, A., LaRusso, N. F., Gores, G. J., & Huebert, R. C. (2025) · Hepatology · doi:10.1097/hep.0000000000001093 · Cited by 38
Self-citationLiu, H., Yin, G., Franco Leonardi, B., Lan, T., Ait Ahmed, Y., Berger, H., Kohlhepp, M. S., Amiridze, N., Martagón Calderón, N., Frau, C., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334425 · Cited by 23
“5 As such, it is increasingly recognised that ductular cells represent more than just bystanders in liver disease progression.”
Krishnan, A., Ozturk, N. B., Cutshaw, K. A., Guicciardi, M. E., Kitagataya, T., Olson, K. E., Pavelko, K. D., Sherman, W., Wixom, A. Q., Jalan-Sakrikar, N., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-52710-3 · Cited by 8
“DR cells are well known to become “activated” and secrete inflammatory mediators 5,20 .”
BackgroundSelf-citationMacrophage heterogeneity in liver fibrosis
Wang, W., Li, S., Liu, Y., Ding, X., Yang, Y., Chen, S., Cao, J., Tacke, F., Dong, W., & Lan, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1639455 · Cited by 8
Metadata
- Authors
- Azad, A. I., Krishnan, A., Troop, L., Li, Y., Katsumi, T., Pavelko, K., Kostallari, E., Guicciardi, M. E., & Gores, G. J.
- Venue
- Hepatology
- Published
- 2020-09
- Volume
- 72
- Issue
- 3
- Pages
- 1013-1028
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W3010261893
- Cited by
- 39
- References
- 14
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.